Critical Contrast: Tango Therapeutics (TNGX) versus Its Rivals

Tango Therapeutics (NASDAQ:TNGX) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Tango Therapeutics to related companies based on the strength of its institutional ownership, earnings, analyst recommendations, risk, valuation, dividends and profitability.

Insider & Institutional Ownership

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.5% of Tango Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Tango Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	2	2	13	0	2.65
Tango Therapeutics Competitors	9869	15284	45613	1598	2.54

Tango Therapeutics presently has a consensus price target of $45.54, indicating a potential upside of 83.25%. As a group, “Biotechnology” companies have a potential upside of 124.64%. Given Tango Therapeutics’ competitors higher probable upside, analysts clearly believe Tango Therapeutics has less favorable growth aspects than its competitors.

Profitability

This table compares Tango Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-30.34%	-28.28%
Tango Therapeutics Competitors	-12,323.33%	-195.91%	-30.60%

Earnings & Valuation

This table compares Tango Therapeutics and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tango Therapeutics	$62.38 million	-$101.59 million	-18.14
Tango Therapeutics Competitors	$700.54 million	$9.44 million	-18.96

Tango Therapeutics’ competitors have higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Tango Therapeutics has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500. Comparatively, Tango Therapeutics’ competitors have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Summary

Tango Therapeutics beats its competitors on 7 of the 12 factors compared.

Tango Therapeutics Company Profile

Tango Therapeutics is a biotechnology company focused on discovering and developing precision medicines for cancer. Based in Cambridge, Massachusetts, the company aims to develop treatments that exploit genetic differences between cancer cells and healthy cells. Its research centers on synthetic lethality, an approach that seeks to identify vulnerabilities created when cancer cells lose or alter particular genes. Tango uses this strategy to find drug targets and develop investigational therapies for tumors with specific genetic alterations.